Research Article
Prevalence of Posttranscatheter Aortic Valve Implantation Vascular Complications in Real Life
Table 1
Baseline characteristics of the studied population.
| | | Whole population (N = 1055) | Post-TAVI vascular complication group (N = 199) | Post-TAVI without vascular complication group (N = 856) | value |
| | Age (mean ± SD) | 84.4 ± 6.9 | 84.8 ± 7.3 | 84.3 ± 6.9 | 0.31 |
| | Sex (N, %) | | | | | | Male | 506 (48) | 97 (48.7) | 409 (47.8) | 0.8 |
| | CVRF (N, %) | | | | | | Systemic hypertension | 733 (69.5) | 150 (75.4) | 538 (68.3) | 0.04 | | Diabetes mellitus | 289 (27.4) | 58 (29.1) | 231 (27) | 0.53 | | Dyslipidemia | 450 (42.7) | 91 (45.7) | 359 (41.9) | 0.33 | | Smoker | 22 (2.1) | 7 (3.5) | 15 (1.8) | 0.11 |
| | NYHA class (N, %) | | | | 0.08 | | I | 16 (1.5) | 3 (1.5) | 13 (1.5) | | | II | 574 (54.4) | 124 (62.3) | 450 (52.6) | | | III | 415 (39.3) | 63 (31.7) | 352 (41.1) | | | IV | 50 (4.7) | 9 (4.5) | 41 (4.8) | |
| | Previous medical history (N, %) | | | | | | Myocardial infarction | 86 (8.2) | 15 (7.5) | 71 (8.3) | 0.72 | | PCI | 209 (19.8) | 38 (19.1) | 171 (20) | 0.77 | | Valvuloplasty | 118 (11.2) | 29 (14.6) | 89 (10.4) | 0.09 | | CABG | 63 (6) | 11 (5.5) | 52 (6.1) | 0.76 | | Stroke | 110 (10.4) | 20 (10.1) | 90 (10.5) | 0.84 | | Peripheral artery disease | 78 (7.4) | 11 (5.5) | 67 (7.8) | 0.26 | | Carotid artery disease | 37 (3.5) | 10 (5) | 27 (3.2) | 0.19 | | Atrial fibrillation | 399 (37.8) | 71 (35.7) | 328 (38.3) | 0.48 | | Chronic respiratory disease | 188 (17.8) | 30 (15.1) | 158 (18.5) | 0.26 |
| | Antithrombotic therapy (N, %) | | | | | | Single antiplatelet | 279 (26.4) | 61 (30.7) | 218 (25.5) | 0.13 | | Dual antiplatelet | 208 (19.7) | 31 (15.6) | 177 (20.7) | 0.1 | | Oral anticoagulant | 256 (24.3) | 48 (24.1) | 208 (24.3) | 0.95 | | Anticoagulant + antiplatelet | 111 (10.5) | 18 (9) | 93 (10.9) | 0.45 |
| | Renal replacement therapy (N, %) | 19 (1.8) | 3 (1.5) | 16 (1.9) | 0.73 | | BMI (mean ± SD) | 26 ± 4.8 | 26.6 ± 6.2 | 25.9 ± 4.7 | 0.06 | | EuroSCORE1 (mean ± SD) | 14.2 ± 9.9 | 14.6 ± 10.9 | 14.1 ± 9.7 | 0.51 | | STS-PROM (mean ± SD) | 6 ± 5.5 | 6.1 ± 5 | 5.9 ± 5.5 | 0.78 |
|
|
∗TAVI: transcatheter aortic valve implantation; CVRF: cardiovascular risk factors; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; BMI: body mass index.
|
